The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approvals for several new medicines and vaccines during its December meeting, including submissions from companies such as Hansoh and Cytokinetics. In a related round of guidance, CHMP also recommended approvals for ImmunityBio's Anktiva and Cytokinetics’ Myqorzo in specified indications. The committee findings affect registration timelines and commercial planning for sponsors across Europe. CHMP positive opinions are a critical step toward European Commission decisions and can influence regulatory strategy in other jurisdictions. Readers should note recommendation details: CHMP opinions vary by indication, and final labeling and conditionalities will be set by the European Commission.